Is Astec Lifesciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astec Lifesciences Ltd is a average quality company .

Is Astec Lifesciences undervalued or overvalued?

The key valuation ratios of Astec Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Astec Lifesciences share price return in the past 10 years?

Astec Lifesciences Ltd share price has appreciated 13.4% annually (CAGR) over the past ten years.

Is Astec Lifesciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Astec Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Astec Lifesciences Ltd - Stock Valuation and Financial Performance

Name: Astec Lifesciences
Brand: Astec Lifesciences

BSE: 533138 | NSE: ASTEC | Pesticides & Agrochemicals | Small Cap

Place order

Astec Lifesciences Share Price

₹903.70 -5.65 -0.62%
as on 18-Jul'25 16:59

Astec Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 533138 | NSE: ASTEC | Pesticides & Agrochemicals | Small Cap

Place order

Astec Lifesciences Share Price

₹903.70 -5.65 -0.62%
as on 18-Jul'25 16:59

10 Year X-Ray of Astec Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10.7%	16.1%	23.8%	20.3%	20.4%	22.3%	22.2%	7.8%	-4.5%	-12.6%	-
Value Creation Index ⓘ	-0.2	0.2	0.7	0.5	0.5	0.6	0.6	-0.5	-1.3	-1.9	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	247	299	368	431	523	555	677	628	458	381	381
Sales YoY Gr.	-	20.9%	23.1%	17.2%	21.3%	6.2%	21.9%	-7.2%	-27.1%	-16.8%	-
Adj EPS ⓘ	2.3	9.6	9.2	17.5	22.2	31.8	42.2	10.1	-25.5	-69.7	-60.1
YoY Gr.	-	324.7%	-5.1%	91.7%	26.5%	43.3%	32.9%	-76.1%	-352%	NA	-
BVPS (₹) ⓘ	59.9	69.9	85.8	102.4	124.8	156.5	200.7	212.2	186.8	118.8	215.9
Adj Net Profit ⓘ	4.5	18.9	18	34.6	43.7	62.7	83.4	20	-50.3	-138	-135
Cash Flow from Ops. ⓘ	-12.5	19.2	64.7	15.3	168	-8.2	23.6	74.7	10.2	-8.4	-
Debt/CF from Ops. ⓘ	-10.1	6.6	1.9	11.5	0.6	-22.9	11.8	4.6	48.3	-66	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.9%	-6.1%	-17.4%	-16.8%
Adj EPS ⓘ	-246.3%	-225.7%	-218.2%	NA
BVPSⓘ	7.9%	-1%	-16.1%	-36.4%
Share Price	13.4%	-1.2%	-24%	-30.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	3.5	14.8	11.7	18.6	19.5	22.6	23.6	4.9	-12.8	-45.6	-35.9
Op. Profit Mgn % ⓘ	13.9	21	18.7	17.8	16.3	20.1	22.8	12.2	-1.3	-17.4	-17.4
Net Profit Mgn % ⓘ	1.8	6.4	4.9	8	8.4	11.3	12.3	3.2	-11	-36.1	-35.3
Debt to Equity ⓘ	1.1	0.9	0.7	0.9	0.4	0.6	0.7	0.8	1.3	2.4	1.2
Working Cap Days ⓘ	304	248	233	223	217	229	244	316	379	368	134
Cash Conv. Cycle ⓘ	105	91	92	95	60	53	102	155	224	238	-20

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -17.40%

Debt to equity has increased versus last 3 years average to 2.36

Sales growth is not so good in last 4 quarters at 0.01%

Latest Financials - Astec Lifesciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-60.2	-60.1
TTM Sales (₹ Cr.)	381	381
BVPS (₹.) ⓘ	215.6	215.9
Reserves (₹ Cr.) ⓘ	461	462
P/BV ⓘ	4.22	4.21
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	631.35 / 1319.33
All Time Low / High (₹)	14.35 / 2269.11
Market Cap (₹ Cr.)	2,038
Equity (₹ Cr.)	22.4
Face Value (₹)	10
Industry PE ⓘ	32

Management X-Ray of Astec Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Astec Lifesciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Key Ratios of Astec Lifesciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	247	299	368	431	523	555	677	628	458	381
Operating Expenses ⓘ	215	236	299	354	437	443	522	552	464	448
Manufacturing Costs	19	22	25	32	39	38	52	64	54	59
Material Costs	161	180	235	279	339	342	387	401	319	297
Employee Cost	16	20	22	25	30	38	50	52	62	61
Other Costs ⓘ	20	14	17	17	30	25	33	35	29	31
Operating Profit ⓘ	32	62	69	76	85	111	154	76	-6	-66
Operating Profit Margin (%)	12.8%	20.9%	18.7%	17.7%	16.3%	20.1%	22.8%	12.1%	-1.3%	-17.4%
Other Income ⓘ	7	3	8	11	12	8	10	13	6	6
Interest ⓘ	13	12	11	12	13	5	9	21	25	37
Depreciation ⓘ	10	14	15	19	23	26	34	34	36	44
Exceptional Items ⓘ	-3	-11	4	0	0	0	0	0	0	0
Profit Before Tax ⓘ	12	29	56	56	61	89	121	35	-62	-141
Tax ⓘ	7	10	21	20	14	24	31	9	-15	-6
Profit After Tax	5	19	35	36	48	65	90	26	-47	-135
PAT Margin (%)	2.1%	6.4%	9.5%	8.3%	9.1%	11.7%	13.3%	4.1%	-10.2%	-35.3%
Adjusted EPS (₹)	2.5	9.7	17.7	18.1	24.1	33.0	45.5	13.0	-23.8	-68.2
Dividend Payout Ratio (%)	0%	15%	8%	8%	6%	5%	3%	12%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund	117	137	169	202	246	309	396	419	369	235
Share Capital ⓘ	19	20	20	20	20	20	20	20	20	20
Reserves ⓘ	98	118	149	182	226	289	377	399	349	215
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	117	126	124	176	99	187	239	296	482	544
Long Term Debt	8	0	0	0	0	40	0	11	199	280
Short Term Debt	109	126	124	176	99	147	239	285	283	264
Trade Payables	68	57	100	63	202	128	190	177	89	82
Others Liabilities ⓘ	25	13	20	20	24	53	100	87	35	26
Total Liabilities ⓘ	328	334	413	461	572	678	925	979	975	887
Fixed Assets
Gross Block	105	124	150	221	271	316	477	488	592	749
Accumulated Depreciation	10	22	35	54	77	103	137	170	206	250
Net Fixed Assetsⓘ	95	103	115	167	194	213	340	318	386	499
CWIP ⓘ	20	8	42	19	24	116	23	127	165	21
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	71	66	78	93	121	106	187	295	196	160
Trade Receivables	81	111	123	122	161	187	274	155	169	147
Cash Equivalents	6	4	1	1	1	2	2	2	2	3
Others Assetsⓘ	55	43	53	59	70	54	100	82	57	57
Total Assets ⓘ	328	334	413	461	572	678	925	979	975	887

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ	-13	19	65	15	168	-8	24	75	10	-8
PBT ⓘ	12	29	56	56	61	89	121	35	-62	-141
Adjustment ⓘ	19	35	18	30	37	29	44	51	63	101
Changes in Working Capital ⓘ	-39	-38	6	-55	88	-103	-112	-6	10	27
Tax Paid ⓘ	-5	-7	-15	-16	-18	-23	-29	-5	-2	5
Cash Flow From Investing Activity ⓘ	-16	-18	-49	-52	-74	-73	-104	-113	-135	-15
Capex	-26	-20	-50	-53	-45	-103	-104	-116	-135	-16
Net Investments	8	2	0	0	0	0	0	0	0	0
Others ⓘ	2	0	1	0	-29	29	0	4	0	1
Cash Flow From Financing Activityⓘ	31	-1	-18	37	-95	81	80	38	125	24
Net Proceeds from Shares ⓘ	0	0	0	0	0	1	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	40	0	16	105	90
Interest Paid ⓘ	-13	-12	-11	-12	-13	-5	-9	-20	-23	-29
Dividend Paid ⓘ	-3	0	-3	-3	-3	-3	-3	-3	-3	0
Others ⓘ	46	11	-5	52	-79	48	92	45	46	-38
Net Cash Flow ⓘ	2	1	-3	0	0	0	0	0	0	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	4.01	15.07	22.9	19.31	21.24	23.46	25.5	6.28	-11.9	-44.64
ROCE (%)	10.65	16.08	23.75	20.31	20.44	22.29	22.21	7.75	-4.5	-12.62
Asset Turnover Ratio	0.72	0.95	0.99	0.99	1.02	0.89	0.85	0.66	0.47	0.42
PAT to CFO Conversion(x)	-2.6	1	1.86	0.42	3.5	-0.12	0.27	2.88	N/A	N/A
Working Capital Days
Receivable Days	136	111	115	103	98	114	124	124	129	148
Inventory Days	106	80	71	72	74	74	79	139	195	167
Payable Days	177	127	122	107	143	176	150	167	152	105

Astec Lifesciences Ltd Stock News

Astec Lifesciences Ltd FAQs

What is the share price of Astec Lifesciences?

Company share prices are keep on changing according to the market conditions. The closing price of Astec Lifesciences on 18-Jul-2025 16:59 is ₹903.7.

What is the market cap of Astec Lifesciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Jul-2025 16:59 the market cap of Astec Lifesciences stood at ₹2,038.2.

What is the P/E ratio of Astec Lifesciences?

The latest P/E ratio of Astec Lifesciences as of 18-Jul-2025 16:59 is 0.00.

What is the P/B ratio of Astec Lifesciences?

The latest P/B ratio of Astec Lifesciences as of 18-Jul-2025 16:59 is 4.22.

What is the 52-week high and low of Astec Lifesciences?

The 52-week high of Astec Lifesciences is ₹1,319.3 and the 52-week low is ₹631.4.

What is the TTM revenue of Astec Lifesciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astec Lifesciences is ₹381.3 ( Cr.) .

About Astec Lifesciences Ltd

Astec is proud of its rich experience of over two decades in the chemical industry. The company employs highly qualified and trained personnel to monitor and maintain its manufacturing activities as well as process development work. Astec prides itself in being responsive, reliable and quick to implement projects. A strong R&D focus has enabled the company to introduce a number of unique products. As the operations are highly integrated both vertically and horizontally, Astec has a very efficient, low cost structure in the market place.

Strong emphasis on quality, backed by a highly competent technical team, has enabled Astec to establish a successful track record in nurturing stable and long term relationships with highly reputed companies in USA, Japan and Europe. Above all, utmost respect for confidentiality, reliability, integrity and commitment in all its business relationships make Astec an ideal outsourcing partner. Astec Chemicals operates an ISO 9001:2000 certified Quality Assurance system.

The company has technologically sophisticated facilities for process development work and has demonstrated its ability to synthesize complex molecules rapidly. All its laboratories are equipped to carry out reactions from gm-scale to kilo-scale {up to 20 litres}.

Scale up to multikilo level is undertaken at its versatile 50-500 lts capacity pilot plant. Setting up a feasibility study through to laboratory development, pilot scale-up and full scale production are governed by the highest safety, quality and environmental standards.

Astec has multipurpose production facilities at two locations.

â€¢ Dombivli (50 km from Mumbai) â€¢ Mahad - two plants ( 180 kms from Mumbai)

They are multi-purpose plants based on 3,000-20,000 litres glasslined and stainless steel reactors. Typical reactors sizes are 10,000 lts.

â€¢ The pilot plant has glass and SS vessels of 50 litres to 500 litres capacity. â€¢ Reactions can be carried out from minus 20o C to 250o C. Distillation up to 300C â€¢ Vacuum down to 1mm Hg. â€¢ Distillation systems can handle high melting solids. â€¢ High efficiency fractionating columns up to 40 theoretical plates are available. â€¢ Facilities are designed to handle a number of corrosive and hazardous raw materials.

Products:

â€¢ Tebuconazole â€¢ Hexaconazole â€¢ Propiconazole â€¢ Metalaxyl â€¢ 1,2 Pentanediol â€¢ Dicap â€¢ 4-Fluoro phenacyl chloride.

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Particulars	Q2FY24 (Rs. Crs)	YoY Trend	Comments
Revenue	111	-44%	Enterprise segment revenues declined 70% while Contract manufacturing revenues rapidly scaled up 3.5x
EBITDA	-3	NA
EBITDA Margin	NA	NA
PAT	-13	NA

Particulars	Q1FY24	YoY trend	Comment
Revenue	143	-23%	While enterprise segment declined 63%, contract manufacturing segment doubled
EBITDA	3	-88%
EBITDA Margin	2%	-1162 bps
PAT	-8	-171%	Pricing pressure and high cost inventories impacted profits

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Astec Lifesciences Ltd - Stock Valuation and Financial Performance

Astec Lifesciences Share Price

Astec Lifesciences Ltd - Stock Valuation and Financial Performance

Astec Lifesciences Share Price

DeciZen - make an informed investing decision on Astec Lifesciences Share

1. Right Stock

2. Right Price

3. Right Time ⓘ

Overall Rating ⓘ

1. Quality

2. Valuation ⓘ

3. Price Trend

Astec Lifesciences stock performance -

Is Astec Lifesciences Ltd an attractive stock to invest in?

1. Is Astec Lifesciences Ltd a good quality company?

2. Is Astec Lifesciences Ltd undervalued or overvalued?

3. Is Astec Lifesciences Ltd a good buy now?

10 Year X-Ray of Astec Lifesciences: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Astec Lifesciences Ltd.

Management X-Ray of Astec Lifesciences: Share

Shareholding Pattern

Promoter's Holding & Share Pledging